| abstract |
It is intended to provide vascular endothelial growth factor (VEGF) inhibitors useful as drugs, in particular, remedies for diseases in which angiogenesis participates (for example, solid cancer and diabetic retinopathy). Namely, novel 3-quinoline-2(1H)-ylideneindolin-2-one derivatives represented by the following general formula (I) or salts thereof have excellent effects of inhibiting VEGF and angiogenesis and an antitumor effect and, therefore, are useful as appropriate VEGF inhibitors, angiogenesis inhibitors and anticancer agents: (I). |